FDA Grants Priority Review to Crizotinib in Relapsed/Refractory ALK-Positive ALCL

September 23, 2020

The FDA accepted a supplemental New Drug Application for crizotinib and granted it a Priority Review as treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma that is positive for an ALK alteration.

HIV-Positivity in Classic Hodgkin Lymphoma Shows Comparable Outcomes to Patients Without HIV

September 11, 2020

Patients with classic Hodgkin lymphoma and human immunodeficiency virus were found to have similar clinical outcomes compared with patients with cHL and no HIV, according to an analysis presented during the eighth annual virtual meeting of the Society of Hematologic Oncology.

FDA to Review sBLA for Axi-Cel in R/R Follicular Lymphoma and Marginal Zone Lymphoma

September 05, 2020

The FDA has accepted a supplemental Biologics License Application for axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma or marginal zone lymphoma after 2 or more prior lines of systemic therapy.

Doctors Debate: Should Asymptomatic Patients With Follicular Lymphoma Be Actively Monitored With Watch-and-Wait Strategy or Immediately Treated?

September 01, 2020

The question of whether patients with asymptomatic advanced-stage follicular lymphoma should undergo watch-and-wait observation or start treatment immediately was addressed at the 2020 Debates and Didactics in Hematology and Oncology during a debate between Jean Louise Koff, MD, MS, and James O. Armitage, MD.

Trial Investigates a Novel Engineered Toxin Body, Lenalidomide Combo in NHL

August 25, 2020

A phase 2a study is recruiting patients with relapsed or refractory B-cell non-Hodgkin lymphoma to receive the combination of MT-3724, a novel CD-20–targeting engineered toxin body and lenalidomide, according to a poster presented at the American Association for Cancer Research Advances in Malignant Lymphoma Meeting.

FDA Accepts NDA for Umbralisib in Lymphomas, Grants Priority Review for MZL

August 13, 2020

The FDA has accepted a New Drug Application for umbralisib as treatment of patients with previously treated marginal zone lymphoma who have received at least 1 prior regimen with anti-CD20 therapy and for patients with follicular lymphoma who have received at least 2 prior systemic therapies.